Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Capital Expenditures: 2013-2024

Historic Capital Expenditures for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Dec 2024 value amounting to $511,000.

  • Viridian Therapeutics, Inc.\DE's Capital Expenditures fell 56.66% to $127,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $369,000, marking a year-over-year decrease of 56.54%. This contributed to the annual value of $511,000 for FY2024, which is 43.10% down from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Capital Expenditures of $511,000 as of FY2024, which was down 43.10% from $898,000 recorded in FY2023.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Capital Expenditures ranged from a high of $898,000 in FY2023 and a low of $42,000 during FY2020.
  • Its 3-year average for Capital Expenditures is $735,333, with a median of $797,000 in 2022.
  • Its Capital Expenditures has fluctuated over the past 5 years, first plummeted by 50.00% in 2020, then soared by 704.76% in 2021.
  • Yearly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Capital Expenditures stood at $42,000 in 2020, then surged by 704.76% to $338,000 in 2021, then surged by 135.80% to $797,000 in 2022, then rose by 12.67% to $898,000 in 2023, then plummeted by 43.10% to $511,000 in 2024.